Navigation Links
US Pharmacopeia announces revised heparin monographs and reference standards
Date:6/23/2008

Rockville, Md., June 23, 2008 The U.S. Pharmacopeial (USP) Convention announces that revised monographs for heparin sodium and heparin calcium in the United States Pharmacopeia (USP) are now available and official on the USP Web site. The revised monographs are accompanied by two new and two updated official USP Reference Standards. These public standards allow any partyand particularly the Food and Drug Administration (FDA) and manufacturersto test heparin sodium and calcium drug substances to assure their quality. All drug manufacturers who market heparin in the United States are required to meet these newly revised standards. The heparin monographs were updated in the interest of public health following the deaths of more than 200 people earlier this year. These deaths are suspected to have resulted from the adulteration of the blood thinner with over-sulfated chondroitin, which is derived from the chemical chondroitin and used in dietary supplements.

The two heparin monographs are posted on the USP Web site at http://www.usp.org/hottopics/heparin.html?hlc. These revisions mark the end of the first stage (Stage 1) of a multi-stage process to revise the monographs. The Stage 1 revision was intended to rapidly address the immediate public health crisis associated with the drug and help ensure an unadulterated supply of heparin by taking proposed methods from the FDA and improving their robustness. The second stage of revision (Stage 2) will seek out additional methods to test for over-sulfated chondroitin and other potential contaminants in heparin. USP co-sponsored a meeting June 19-20, 2008, in Strasbourg, France, with the European Directorate for the Quality of Medicines (the organization that elaborates the European Pharmacopoeia) and the United Kingdom's National Institute for Biological Standards and Control as part of a coordinated, worldwide effort to assure the quality and purity of heparin.

"The expedited revision of USP's heparin standards gives manufacturers, health care practitioners and patients increased confidence that this widely used drug is free of this adulterant," said Roger L. Williams, M.D., USP executive vice president and CEO. "The monograph revisions were completed quickly to alleviate a major public health concern; they were accomplished through USP's established, transparent, and scientific process. In updating the standards, USP received guidance not only from the FDA but also from the volunteer experts on USP's Heparin Advisory Panel and USP's Blood and Blood Products Expert Committee, which concluded the monograph standards, and USP's Reference Standards Committee, which endorsed the physical standards. USP thanks these colleagues and the many other national and international experts who assisted the USP Council of Experts' Expert Committees and Advisory Panel and worked with us to meet this extremely important challenge."

USP publishes official quality standards for medicines in the United States PharmacopeiaNational Formulary (USPNF) and has worked with FDA for more than 100 years in a unique public-private partnership that helps to assure the quality of medicines in the United States. The availability of a good public monograph in the USPNF along with allied reference materials is one of a series of safety nets that help assure that U.S. patients and practitioners have access to good quality medicines.

"While USP monographs are generally designed to test for known impurities that may result from the manufacturing process or degradation, and not for unknown contaminants that may be added either accidentally or deliberately, we were pleased to modify our standards to help alleviate patient danger associated with the heparin product and will continue to explore methods for detecting potential contaminants," Dr. Williams noted.


'/>"/>

Contact: Laura Provan
lnp@usp.org
301-816-8268
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. U.S. Pharmacopeia Aiding FDA in Improved Tests for Heparin Contamination
2. U.S. Pharmacopeia Releases New Edition of the Food Chemicals Codex
3. US Pharmacopeia releases new edition of the Food Chemicals Codex
4. Pharmacopeia to Present at The Roth 20th Annual OC Growth Stock Conference
5. USP publishes Spanish edition of United States Pharmacopeia and National Formulary
6. USP Publishes Spanish Edition of United States Pharmacopeia and National Formulary
7. U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide
8. US Pharmacopeia partners with Quantros to enhance the MEDMARX patient safety reporting program
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
11. Pharmacopeia Announces Senior Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... 2017 , ... Medicare doesn’t have the authority to negotiate ... their prescription drugs, according to a new comparison of drug plans by ... there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare policy ...
(Date:9/20/2017)... ... 20, 2017 , ... “Finn Mouseson”: follows the exciting story of a mouse ... mouse sets out on a journey that will show that friends are to be ... newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe for ... of published author, Brooks Rathell. , “We typically hear about the favor of God. ... favor of God. Not only does it exist, but it is meant for you. ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a ... leader, Denise Flannery, to its strategic advisory and client development team. , ... work with clients across different industries to develop and implement market-justified strategies, modernize ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... -- ivWatch, LLC, the leading provider of continuous monitoring devices for ... awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven ... ... early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology: